News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
FORMA Therapeutics, Inc. Teams with TGen Drug Development Services (TD2)
June 18, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WATERTOWN, Mass. & SCOTTSDALE, Ariz.--(BUSINESS WIRE)--FORMA Therapeutics and TGen Drug Development (TD2) today announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both organizations.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
MORE ON THIS TOPIC
Mergers & acquisitions
Regeneron Backs Off 23andMe, Losing Bid to Former CEO
June 16, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus
June 16, 2025
·
2 min read
·
Annalee Armstrong
Artificial intelligence
AstraZeneca Makes $5.3B AI Bet With China’s CSPC for Chronic Disease Pills
June 13, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
BioNTech Swallows Vaccine Rival CureVac in $1.25B All-Stock Acquisition
June 12, 2025
·
3 min read
·
Tristan Manalac